

Amendments to the Specification:

Please replace the paragraph beginning at page 5, line 15, with the following:

Figure 9 represents the decreased toxicity of the LL2-ONCONASE® immunotoxin when compared to ONCONASE® alone and IT-dgRTA (RFB4-deglycosylated Ricin A chain). The drugs were administered every 2 hours. 4X/day for 5 days. The arrows indicate the days the mice with each respective treatment were found dead, *i.e.*, the mouse treated with 30 mg/kg ONCONASE® was found dead on day 4 and the mouse treated with 50 mg/kg IT-dgRTA was found dead on day 7. In RFB4-PE35KDEL, KDEL = SEQ ID NO:4.

Please replace the paragraph (**Table 5**) beginning at page 30, line 12, with the following:

--**Table 5: In vivo Cytotoxicity of LL2-ONCONASE Immunotoxins**

Toxicity in Mice		
Dose Schedule	Total Dose (μg)	Death/Total
LL2-PE38KDEL*		
80 μg i.p. x 1	80	2/2
35 μg i.p. QD x 4	140	2/2
LL2-ONCONASE		
100 μg i.p x 1	100	0/3
100 μg i.p. QOD x 5	500	0/3
100 μg i.p. QD x 5	500	0/3
500 μg i.p. x 1	500	0/3

* Kreitman, *et al.*, *Cancer Res.* 53:819 (1993). In LL2-PE38KDEL, KDEL = SEQ ID NO:4.

QD = daily

QOD = every other day--

Appl. No. 09/918,887
Amdt. dated August 14, 2003
Reply to Notice to Comply of July 16, 2003

PATENT

Please cancel the present "SEQUENCE LISTING", pages 1-3, submitted July 30, 2001, and insert therefor the accompanying paper copy of the Substitute Sequence Listing, page numbers 1 and 2, at the end of the application.